SouthernSun Asset Management, LLC, an investment management firm, released its “SouthernSun Small Cap Strategy” third quarter ...

Analyst Michael Petusky of Barrington maintained a Buy rating on US Physical Therapy (USPH – Research Report), retaining the price target ...

Compass Pathways is advancing pivotal trials to test psilocybin's impact on treatment-resistant depression. See why I rate ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating yesterday. Sami Corwin has given his ...

Q3 2024 Earnings Call Nov 08, 2024, 8:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants. Prepar ...

MaxCyte now expects full year 2024 core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year ...

Stock-based compensation decreased by approximately $340 thousand in the three months ended September 30, 2024, compared to the three months ended September 30, 2023, primarily due to stock options ...